Clinical trial
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With…
NCT00262067 · Genentech, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00262067 |
|---|---|
| Title | A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) |
| Official title | A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Placebo, Chemotherapy |
| Enrollment | 1,237 |
| Start date | Dec 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Dec 1, 2013 |
| First posted | Dec 6, 2005 |
| Last update posted | Dec 13, 2013 |
| Countries | Australia, Brazil, Canada, France, Greece, Guatemala, Mexico, Netherlands, Norway, Panama, Peru, Philippines and 10 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: